BG60256B1 - Рекомбинантен метод за получаване на лимфотоксин - Google Patents

Рекомбинантен метод за получаване на лимфотоксин

Info

Publication number
BG60256B1
BG60256B1 BG070460A BG7046085A BG60256B1 BG 60256 B1 BG60256 B1 BG 60256B1 BG 070460 A BG070460 A BG 070460A BG 7046085 A BG7046085 A BG 7046085A BG 60256 B1 BG60256 B1 BG 60256B1
Authority
BG
Bulgaria
Prior art keywords
lymphotoxin
new
recombinant method
lymphotoxins
immobilized
Prior art date
Application number
BG070460A
Other languages
English (en)
Other versions
BG60256B2 (bg
Inventor
Bharat Aggarwal
Timothy BRINGMAN
Patrick Gray
Glenn Nedwin
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/616,502 external-priority patent/US4959457A/en
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of BG60256B2 publication Critical patent/BG60256B2/bg
Publication of BG60256B1 publication Critical patent/BG60256B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Лимфотоксинът намира приложение в медицината и проявява токсичен ефект спрямо туморните клетки. Биологично активен лимфотоксин се синтезира в рекомбинантни клетки. Създадени са нови нуклеинови киселини и вектори. По метода икономично се приготвят препарати, съдържащи еднакви лимфотоксинови полипептиди и производни на лимфотоксина, които имат аминокиселинна последователност, различна от естествената. Лимфотоксините са пречистени до специфична активност 2-10 х 107 единици/мг белтък чрез пречистване с нови, имобилизирани лимфотоксиннеутрализиращи моноклонални антитела. 51 претенции
BG070460A 1984-05-31 1985-05-30 Рекомбинантен метод за получаване на лимфотоксин BG60256B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61650384A 1984-05-31 1984-05-31
US06/616,502 US4959457A (en) 1984-05-31 1984-05-31 Anti-lymphotoxin
US73231285A 1985-05-09 1985-05-09

Publications (2)

Publication Number Publication Date
BG60256B2 BG60256B2 (bg) 1994-03-24
BG60256B1 true BG60256B1 (bg) 1994-03-24

Family

ID=27417179

Family Applications (1)

Application Number Title Priority Date Filing Date
BG070460A BG60256B1 (bg) 1984-05-31 1985-05-30 Рекомбинантен метод за получаване на лимфотоксин

Country Status (23)

Country Link
EP (2) EP0164965B1 (bg)
JP (3) JP2521703B2 (bg)
AR (1) AR245219A1 (bg)
AT (2) ATE195323T1 (bg)
AU (1) AU599303B2 (bg)
BG (1) BG60256B1 (bg)
CA (1) CA1340641C (bg)
CZ (1) CZ283148B6 (bg)
DE (2) DE3587597T2 (bg)
DK (1) DK171531B1 (bg)
ES (1) ES8802182A1 (bg)
FI (1) FI93025C (bg)
GR (1) GR851317B (bg)
HU (1) HU204085B (bg)
IE (1) IE63487B1 (bg)
IL (1) IL75318A (bg)
NO (1) NO179075C (bg)
NZ (1) NZ212207A (bg)
PL (1) PL155410B1 (bg)
PT (1) PT80573B (bg)
RO (1) RO100383A2 (bg)
SK (1) SK278333B6 (bg)
YU (1) YU47735B (bg)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU45104B (en) 1980-04-03 1992-03-10 Biogen Nv Process for producing recombinant dnk molecule, capable of inducting polypeptide expression in an one-cell host
IL75318A (en) 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
US5683688A (en) 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
ATE73856T1 (de) * 1984-12-21 1992-04-15 Biogen Inc Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren.
JPS62111928A (ja) * 1985-10-15 1987-05-22 Kanegafuchi Chem Ind Co Ltd 新規リンホトキシン
JPS62195285A (ja) * 1986-02-19 1987-08-28 Kanegafuchi Chem Ind Co Ltd リンホトキシン発現ベクタ−及びそれを用いるリンホトキシンの製造方法
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
JP2548204B2 (ja) * 1987-06-27 1996-10-30 電気化学工業株式会社 新生理活性ポリペプチド
EP0230781B1 (en) * 1985-12-24 1992-07-22 Denki Kagaku Kogyo Kabushiki Kaisha Lymphotoxin gene, method for its production, and lymphotoxin
US5403725A (en) * 1985-12-24 1995-04-04 Denki Kagaku Kogyo Kabushiki Kaisha Method for production of lymphotoxin (TNFB) in cell line A-C5-8
EP0230574A3 (en) * 1986-01-31 1989-03-22 Yale University Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof
JPS62181298A (ja) * 1986-02-05 1987-08-08 Kyowa Hakko Kogyo Co Ltd ヒトリンホトキシンポリペプチド誘導体
DE3620656A1 (de) * 1986-06-20 1987-12-23 Basf Ag Polypeptide mit lymphotoxin-aktivitaet oder lymphotoxin-aehnlicher aktivitaet, ihre herstellung und verwendung
JPS63105680A (ja) * 1986-10-22 1988-05-10 Kanegafuchi Chem Ind Co Ltd ヒト・リンホトキシン発現ベクタ−、該発現ベクタ−による形質転換細胞および該細胞を用いるリンホトキシンの製造方法
EP0272894A3 (en) * 1986-12-24 1989-06-14 Takeda Chemical Industries, Ltd. Recombinant human lymphotoxin
US5175268A (en) * 1986-12-24 1992-12-29 Takeda Chemical Industries, Ltd. DNA encoding recombinant human lymphotoxin
FI884798A (fi) * 1987-10-28 1989-04-29 Eisai Co Ltd Rekombinantlymfotoxin.
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217326B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene encoding human tumour necrosis factor beta.
EP0338497A3 (en) * 1988-04-22 1990-05-16 Takeda Chemical Industries, Ltd. Bispecific hybrid monoclonal antibody
JPH023698A (ja) * 1988-06-20 1990-01-09 Denki Kagaku Kogyo Kk ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬
CA2001756A1 (en) * 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant
JPH03106821A (ja) * 1989-09-20 1991-05-07 Denki Kagaku Kogyo Kk 抗腫瘍剤
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
ATE219945T1 (de) * 1995-01-23 2002-07-15 Xenotech Inc Zusammensetzung zur verhinderung von osteolyse und metastasen
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
DK1045906T3 (da) 1998-01-15 2009-02-16 Genentech Inc APO-2-ligand
US20070048301A1 (en) * 2002-11-26 2007-03-01 Bodary-Winter Sarah C Compositions and methods for the treatment of immune related diseases
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
EP1699486A4 (en) * 2003-12-08 2007-07-18 Centocor Inc ANTI-LYMPHOTOXIN HUMAN ALPHA ANTIBODIES, COMPOSITIONS, METHODS AND USES
CA2560742A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
AR063257A1 (es) * 2006-10-12 2009-01-14 Genentech Inc Anticuerpos anti-linfotoxina alfa
JP2010506955A (ja) 2006-10-20 2010-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 可溶性リンホトキシンβレセプターによる脱髄障害の処置
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
WO2015164859A1 (en) * 2014-04-25 2015-10-29 Naurex, Inc. Stable compositions of neuroactive peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88257I2 (bg) * 1978-12-22 1994-02-03
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
ZA834976B (en) * 1982-07-30 1984-08-29 Genentech Inc Human lymphotoxin
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
DE3331108A1 (de) * 1983-08-30 1985-05-02 Boehringer Ingelheim International GmbH, 6507 Ingelheim Verfahren zur herstellung von lymphotoxin und von lymphotoxin-mrna
EP0135797A3 (de) * 1983-08-30 1987-11-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung von Lymphotoxin und von Lymphotoxin-mRNA
IL75318A (en) 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production

Also Published As

Publication number Publication date
SK393085A3 (en) 1996-11-06
CZ393085A3 (en) 1997-07-16
HU204085B (en) 1991-11-28
DE3587597T2 (de) 1994-06-01
PL155410B1 (en) 1991-11-29
AR245219A1 (es) 1993-12-30
DE3588225T2 (de) 2001-04-05
EP0509553B1 (en) 2000-08-09
FI852143A0 (fi) 1985-05-29
JPS6156197A (ja) 1986-03-20
IE930589L (en) 1985-11-30
EP0164965B1 (en) 1993-09-29
IE851321L (en) 1985-11-30
CA1340641C (en) 1999-07-13
CZ283148B6 (cs) 1998-01-14
GR851317B (bg) 1985-11-25
YU91985A (en) 1988-12-31
IL75318A (en) 1994-08-26
NZ212207A (en) 1991-07-26
BG60256B2 (bg) 1994-03-24
ATE195323T1 (de) 2000-08-15
JPH07291995A (ja) 1995-11-07
RO100383B1 (ro) 1991-03-01
DK171531B1 (da) 1996-12-23
ES8802182A1 (es) 1988-04-16
JPH07250692A (ja) 1995-10-03
AU4320385A (en) 1985-12-05
FI93025B (fi) 1994-10-31
AU599303B2 (en) 1990-07-19
NO179075B (no) 1996-04-22
NO852173L (no) 1985-12-02
EP0164965A2 (en) 1985-12-18
JP2804237B2 (ja) 1998-09-24
YU47735B (sh) 1996-01-08
FI93025C (fi) 1995-02-10
DE3588225D1 (de) 2000-09-14
IL75318A0 (en) 1985-09-29
DE3587597D1 (de) 1993-11-04
IE63487B1 (en) 1995-05-03
DK241385D0 (da) 1985-05-30
HUT37814A (en) 1986-02-28
ES543695A0 (es) 1988-04-16
SK278333B6 (en) 1996-11-06
PL253739A1 (en) 1986-03-11
PT80573B (pt) 1987-08-19
JP2521703B2 (ja) 1996-08-07
RO100383A2 (ro) 1991-10-17
PT80573A (en) 1985-06-01
NO179075C (no) 1996-07-31
EP0509553A1 (en) 1992-10-21
DK241385A (da) 1985-12-01
ATE95243T1 (de) 1993-10-15
EP0164965A3 (en) 1988-04-06
FI852143L (fi) 1985-12-01

Similar Documents

Publication Publication Date Title
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
Lozier et al. Complete amino acid sequence of human plasma beta 2-glycoprotein I.
Duckworth et al. Purification of insulin-specific protease by affinity chromatography
Robey et al. Proteolysis of human C-reactive protein produces peptides with potent immunomodulating activity.
DE69112207D1 (en) "walk-through"-mutagenese.
ATE171216T1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
AU590896B2 (en) Improved formulations for recombinant beta-interferon
KR880701288A (ko) M-csf의 제법
ATE80166T1 (de) Verfahren zur isolierung rekombinanter polypeptide in biologisch aktiver form.
EP0134385A3 (en) A protein having cell growth stimulating action, composition thereof and method for producing the same
ATE121752T1 (de) Entfernung von protein a aus antikörper- präparationen.
Pickering et al. Adrenocorticotropin XXVII. On the presence of pig-tyre adrenocorticotropin in sheep pituitaries, and a simple method for the isolation of αs-adrenocorticotropin
ATE113960T1 (de) Proteingewinnung.
KR890001581A (ko) 조직인자 억제제
FI101476B1 (fi) Menetelmä kalsiumista riippuvan proteiini C:n vastaisen monoklonaalisen vasta-aineen valmistamiseksi
Church et al. Identification of two distinct species of procollagen synthesized by a clonal line of calf dermatosparactic cells
US4613459A (en) Lymphocyte growth factor
ES2081817T3 (es) Polipeptido con secuencias principales repetidas que se fijan en la celula.
KR860002526A (ko) 단백질의 상호 분리 방법
ATE89317T1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
DE3151738C2 (bg)
Stathakis et al. Human fibrinogen heterogeneities. Preparation and characterization of γ and γ′ chains
GB9311454D0 (en) Pharmaceutical compositions
ATE119914T1 (de) Peptide, deren verwendung als immuno- suppressanten und verfahren zu deren herstellung.
DK0383599T3 (da) Protein-anticancermiddel